Cargando…
The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
INTRODUCTION: Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sum of tamoxifen and all its metabolites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam, endoxifen) both have ER...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395096/ https://www.ncbi.nlm.nih.gov/pubmed/25867603 http://dx.doi.org/10.1371/journal.pone.0122339 |
_version_ | 1782366368770818048 |
---|---|
author | Helland, Thomas Gjerde, Jennifer Dankel, Simon Fenne, Ingvild S. Skartveit, Linn Drangevåg, Andreas Bozickovic, Olivera Flågeng, Marianne Hauglid Søiland, Håvard Mellgren, Gunnar Lien, Ernst A. |
author_facet | Helland, Thomas Gjerde, Jennifer Dankel, Simon Fenne, Ingvild S. Skartveit, Linn Drangevåg, Andreas Bozickovic, Olivera Flågeng, Marianne Hauglid Søiland, Håvard Mellgren, Gunnar Lien, Ernst A. |
author_sort | Helland, Thomas |
collection | PubMed |
description | INTRODUCTION: Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sum of tamoxifen and all its metabolites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam, endoxifen) both have ER affinity exceeding that of the parent drug tamoxifen. 4OHNDtam is considered the main active metabolite of tamoxifen. Ndesmethyltamoxifen (NDtam) is the major tamoxifen metabolite. It has low affinity to the ER and is not believed to influence tumor growth. However, NDtam might mediate adverse effects of tamoxifen treatment. In this study we investigated the gene regulatory effects of the three metabolites of tamoxifen in MCF-7 breast cancer cells. MATERIAL AND METHODS: Using concentrations that mimic the clinical situation we examined effects of 4OHtam, 4OHNDtam and NDtam on global gene expression in 17β-estradiol (E(2)) treated MCF-7 cells. Transcriptomic responses were assessed by correspondence analysis, differential expression, gene ontology analysis and quantitative real time PCR (Q-rt-PCR). E(2) deprivation and knockdown of Steroid Receptor Coactivator-3 (SRC-3)/Amplified in Breast Cancer 1 (AIB1) mRNA in MCF-7 cells were performed to further characterize specific effects on gene expression. RESULTS: 4OHNDtam and 4OHtam caused major changes in gene expression compared to treatment with E(2) alone, with a stronger effect of 4OHNDtam. NDtam had nearly no effect on the global gene expression profile. Treatment of MCF-7 cells with 4OHNDtam led to a strong down-regulation of the CytoKeratin 6 isoforms (KRT6A, KRT6B and KRT6C). The CytoKeratin 6 mRNAs were also down-regulated in MCF-7 cells after E(2) deprivation and after SRC-3/AIB1 knockdown. CONCLUSION: Using concentrations that mimic the clinical situation we report global gene expression changes that were most pronounced with 4OHNDtam and minimal with NDtam. Genes encoding CytoKeratin 6, were highly down-regulated by 4OHNDtam, as well as after E(2) deprivation and knockdown of SRC-3/AIB1, indicating an estrogen receptor-dependent regulation. |
format | Online Article Text |
id | pubmed-4395096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43950962015-04-21 The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells Helland, Thomas Gjerde, Jennifer Dankel, Simon Fenne, Ingvild S. Skartveit, Linn Drangevåg, Andreas Bozickovic, Olivera Flågeng, Marianne Hauglid Søiland, Håvard Mellgren, Gunnar Lien, Ernst A. PLoS One Research Article INTRODUCTION: Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sum of tamoxifen and all its metabolites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam, endoxifen) both have ER affinity exceeding that of the parent drug tamoxifen. 4OHNDtam is considered the main active metabolite of tamoxifen. Ndesmethyltamoxifen (NDtam) is the major tamoxifen metabolite. It has low affinity to the ER and is not believed to influence tumor growth. However, NDtam might mediate adverse effects of tamoxifen treatment. In this study we investigated the gene regulatory effects of the three metabolites of tamoxifen in MCF-7 breast cancer cells. MATERIAL AND METHODS: Using concentrations that mimic the clinical situation we examined effects of 4OHtam, 4OHNDtam and NDtam on global gene expression in 17β-estradiol (E(2)) treated MCF-7 cells. Transcriptomic responses were assessed by correspondence analysis, differential expression, gene ontology analysis and quantitative real time PCR (Q-rt-PCR). E(2) deprivation and knockdown of Steroid Receptor Coactivator-3 (SRC-3)/Amplified in Breast Cancer 1 (AIB1) mRNA in MCF-7 cells were performed to further characterize specific effects on gene expression. RESULTS: 4OHNDtam and 4OHtam caused major changes in gene expression compared to treatment with E(2) alone, with a stronger effect of 4OHNDtam. NDtam had nearly no effect on the global gene expression profile. Treatment of MCF-7 cells with 4OHNDtam led to a strong down-regulation of the CytoKeratin 6 isoforms (KRT6A, KRT6B and KRT6C). The CytoKeratin 6 mRNAs were also down-regulated in MCF-7 cells after E(2) deprivation and after SRC-3/AIB1 knockdown. CONCLUSION: Using concentrations that mimic the clinical situation we report global gene expression changes that were most pronounced with 4OHNDtam and minimal with NDtam. Genes encoding CytoKeratin 6, were highly down-regulated by 4OHNDtam, as well as after E(2) deprivation and knockdown of SRC-3/AIB1, indicating an estrogen receptor-dependent regulation. Public Library of Science 2015-04-13 /pmc/articles/PMC4395096/ /pubmed/25867603 http://dx.doi.org/10.1371/journal.pone.0122339 Text en © 2015 Helland et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Helland, Thomas Gjerde, Jennifer Dankel, Simon Fenne, Ingvild S. Skartveit, Linn Drangevåg, Andreas Bozickovic, Olivera Flågeng, Marianne Hauglid Søiland, Håvard Mellgren, Gunnar Lien, Ernst A. The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells |
title | The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells |
title_full | The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells |
title_fullStr | The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells |
title_full_unstemmed | The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells |
title_short | The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells |
title_sort | active tamoxifen metabolite endoxifen (4ohndtam) strongly down-regulates cytokeratin 6 (ck6) in mcf-7 breast cancer cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395096/ https://www.ncbi.nlm.nih.gov/pubmed/25867603 http://dx.doi.org/10.1371/journal.pone.0122339 |
work_keys_str_mv | AT hellandthomas theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT gjerdejennifer theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT dankelsimon theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT fenneingvilds theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT skartveitlinn theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT drangevagandreas theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT bozickovicolivera theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT flagengmariannehauglid theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT søilandhavard theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT mellgrengunnar theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT lienernsta theactivetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT hellandthomas activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT gjerdejennifer activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT dankelsimon activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT fenneingvilds activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT skartveitlinn activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT drangevagandreas activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT bozickovicolivera activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT flagengmariannehauglid activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT søilandhavard activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT mellgrengunnar activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells AT lienernsta activetamoxifenmetaboliteendoxifen4ohndtamstronglydownregulatescytokeratin6ck6inmcf7breastcancercells |